Galanin modulating effect on restraint stress-induced short- and long-term behavioral changes in Wistar rats

Neuroscience Letters

Volumn 502, Issue 3, 2011, Pages 147-151

  Klenerova, Vera ^a   Flegel, Martin ^a   Skopek, Petr ^a   Sida, Pavel ^a   Hynie, Sixtus ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Anti anxiety effects; Anti stress effects; Galanin; Open space testing; Rat behavior; Restraint stress

Indexed keywords

GALANIN; PROTEIN INHIBITOR;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DRUG EFFECT; EXPLORATORY BEHAVIOR; IMMOBILIZATION STRESS; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REARING; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EXPLORATORY BEHAVIOR; GALANIN; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; RESTRAINT, PHYSICAL; STRESS, PSYCHOLOGICAL; TIME; TIME FACTORS;

EID: 80052348920     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.06.051     Document Type: Article

References (47)

1. Barrera G., Hernandez A., Poulin J., Laforest S., Drolet G., Morilak D. Galanin mediated anxiolytic effect in rat central amygdala is not a result of corelease from noradrenergic terminals. Synapse 2006, 59:27-40.
2. Bartfai T., Fisone G., Langel U. Galanin and galanin antagonists: molecular and biochemical perspectives. Trends Pharmacol. Sci. 1992, 13:312-317.
3. Begley D.J. Peptides and the blood-brain barrier: the status of our understanding. Ann. N. Y. Acad. Sci. 1994, 739:89-100.
4. Bert B., Fink H., Sohr R., Rex A. Different effects of diazepam in Fisher rats and two stocks of Wistar rats in test for anxiety. Pharmacol. Biochem. Behav. 2001, 70:411-420.
5. Bing O., Moller C., Engel J.A., Soderpalm B., Hellig M. Anxiolytic-like action of centrally administered galanin. Neurosci. Lett. 1993, 164:17-20.
6. Blume A., Bosch O.J., Miklos S., Tomer L., Wales L., Waldherr M., Neumann I.G. Oxytocin reduces anxiety via ERK1/2 activation: local effect within the rat hypothalamic paraventricular nucleus. Eur. J. Neurosci. 2008, 27:1947-1956.
7. Broadwell R.D., Balin B.J., Salcman M. Transcytosis through the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:632-636.
8. Counts S.E., Perez S.E., Mufson E.J. Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective?. Cell. Mol. Life Sci. 2008, 65:1842-1853.
9. Crawley J.N., Robinson J.K., Langel U., Bartfai T. Galanin receptor antagonists M40 and C7 block galanin-induced feeding. Brain Res. 1993, 600:268-272.
10. Dvorska I., Brust P., Hrbas P., Ruhle H.J., Barth T., Ermisch A. On the blood-brain barrier to peptides: effects of immobilization stress on regional blood supply and accumulation of labelled peptides in the rat brain. Endocr. Regul. 1992, 26:77-82.
11. Gimpl G., Fahrenholz F. The oxytocin receptor system. Physiol. Rev. 2001, 81:629-683.
12. Holmes A., Kinney J.W., Wrenn C.C., Li Q., Yang R.J., Ma L., Vishwanath J., Saavedra M.C., Innerfield C.E., Jacoby A.S., Shine J., Iismaa T.P., Crawley J.E. Galanin-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated-plus maze. Neuropsychopharmacology 2003, 28:1031-1044.
13. Holmes A., Picciotto M.R. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction. CNS Neurol. Disord. Drug Targets 2006, 5:225-232.
14. Karlsson R.M., Holmes A. Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease. Amino Acids 2006, 31:231-239.
15. Khosbouei H., Cecchi M., Dove S., Javors M., Morilak D.A. Behavioral reactivity to stress: amplification of stress-induced noradrenergic activation elicits a galanin-mediated anxiolytic effect in central amygdala. Pharmacol. Biochem. Behav. 2002, 71:407-417.
16. Khosbouei H., Cecchi M., Morilak D.A. Modulatory effects of galanin in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuropsychopharmacology 2002, 27:25-34.
17. Klenerová V., Krejčí I., Šída P., Hliňák Z., Hynie S. Timing of stress and testing influence the long-lasting behavioral performance in rats. Neurosci. Lett. 2006, 410:100-104.
18. Klenerova V., Krejci I., Sida P., Hlinak Z., Hynie S. Oxytocin and carbetocin effects on spontaneous behavior of male rats: modulation by oxytocin receptor antagonists. Neuroendocrinol. Lett. 2009, 30:335-342.
19. Klenerová V., Krejčí I., Šída P., Hliňák Z., Hynie S. Modulatory effects of oxytocin and carbetocin on stress-induced changes in rat behavior in the open-field. J. Physiol. Pharmacol. 2009, 60:57-62.
20. Klenerova V., Krejci I., Sida P., Hlinak Z., Hynie S. Oxytocin and carbetocin ameliorating effects on restraint stress-induced short- and long-term behavioral changes in rats. Neuroendocrinol. Lett. 2010, 31:622-630.
21. Klenerová V., Šída P., Krejčí I., Hliňák Z., Hynie S. Effects of two types of restraint stress on spontaneous behavior of Sprague-Dawley and Lewis rats. J. Physiol. Pharmacol. 2007, 58:83-94.
22. Kozlovski N., Matar M.A., Kaplan Z., Zohar J., Cohen H. The role of the galaninergic system in modulating stress-related responses in animal model of posttraumatic stress disorder. Biol. Psychiatry 2009, 65:383-391.
23. Lang R., Gundlach A.L., Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol. Ther. 2007, 115:177-207.
24. Lu X., Barr A.M., Kinney J.W., Sanna P., Conti B., Behrens M.M., Bartfai T. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:874-879.
25. Mathew S.J., Price R.B., Charney D.S. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am. J. Med. Genet. Part C: Semin. Med. Genet. 2008, 148C:83-98.
26. McDonald M., Crawley J. Galanin receptor antagonist M40 blocks galanin-induced choice accuracy deficits on a delayed-nonmatching-to-position task. Behav. Neurosci. 1996, 110:125-132.
27. McDonald M.P., Willard L.B., Wenk G.L., Crawley J.N. Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy for rats with cholinergic lesions. J. Neurosci. 1998, 18:5078-5085.
28. Mitsukawa K., Lu X., Bartfai T. Galanin, galanin receptors and drug targets. Cell. Mol. Life Sci. 2008, 65:1796-1805.
29. Morilak D.A., Cecchi M., Khosbouei H. Interactions of norepinephrine and galanin in the central amygdala and lateral bed nucleus of the stria terminalis modulate the behavioral response to acute stress. Life Sci. 2003, 73:715-726.
30. Moller C., Sommer W., Thorsell A., Hellig M. Anxiogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacology 1999, 21:507-512.
31. Moller C., Wiklund L., Sommer W., Thorsell A., Helaling M. Decreased experimental anxiety and voluntary ethanol consumption in rats following central but not basolateral amygdala lesions. Brain Res. 1997, 760:94-101.
32. Murck H., Held K., Ziegebein M., Kunzel H., Holsboer F., Steiger A. Intravenous administration of the neuropeptide galanin has fast antidetressant efficacy and affects the sleep EEG. Psychoneuroendoctinology 2004, 29:1205-1211.
33. Neumann I.D. Involvement in the brain oxytocin system in stress coping: interactions with the hypothalamo-pituitary-adrenal axis. Prog. Brain Res. 2002, 139:147-162.
34. Neumann I.D., Kromer S.A., Toschi A., Ebner K. Brain oxytocin inhibits the (re)activity of the hypothalamo-pituitary-adrenal axis in male rats: involvement of hypothalamic and limbic brain regions. Regul. Pept. 2000, 96:31-38.
35. Neumann I.D., Veenema1 A.H., Beiderbeck D.I. Aggression and anxiety: social context and neurobiological links. Front. Behav. Neurosci. 2010, 4:1-16. (Article 12).
36. Partridge W.M. Receptor-mediated peptide transport through the blood-brain barrier. Endocr. Rev. 1986, 7:314-330.
37. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 2003, 403:3-33.
38. Ramos A., Correia E.C., Izidio G.S., Brüske G.R. Genetic selection of two new rat lines displaying different levels of anxiety-related behaviors. Behav. Genet. 2003, 33:657-668.
39. Ring R.H., Malberg J.E., Potestio L., Ping J., Bolkess S., Luo B., Schechter L.E., Rizzo S., Rahman Z., Rosenzweig-Lipson S. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 2006, 185:218-225.
40. Rotzinger S., Lovejoy D.A., Tan L.A. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 2010, 31:736-756.
41. Slattery D.A., Neumann I.D. Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats. Neuropharmacology 2010, 58:56-61.
42. United States Patent Application 20080033045, Use of a galanin peptide as a therapeutic agent (2008).
43. US Patent 6894026, Long acting oxytocin analogue for the treatment and prevention of Breast cancer and psychiatric disorders, Issued on May 17 (2005).
44. Uvnas-Moberg K., Ahlenius A.S., Hillegaart V., Alster P. High doses of oxytocin cause sedation and low doses cause an anxiolytic-like effect in male rats. Pharmacol. Biochem. Behav. 1994, 49:101-106.
45. Windle R.J., Shanks S.L., Lightman S.L., Ingram C.D. Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology 1997, 138:2829-2834.
46. Windle R.J., Gamble L.E., Kershaw Y.M., Wood S.A., Lightman S.L., Ingram C.D. Gonadal steroid modulation of stress-induced hypothalamo-pituitary adrenal activity and anxiety behavior: role of oxytocin. Endocrinology 2006, 147:2423-2431.
47. Wrenn C.C., Holmes A. The role of galanin in modulating stress-related neural pathways. Drug News Perspect. 2006, 19:461-467.